Natera's personalized, tumor-informed molecular residual disease (MRD) test is being used in a phase III trial to identify breast cancer patients who are eligible for investigational treatment with niraparib.
Signatera was used to screen the first patient in GlaxoSmithKline's Zest Study. The trial aims to test the efficacy and safety of treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib after surgery or adjuvant therapy in 800 patients with triple-negative breast cancer or HR-positive/HER2-negative, BRCA-mutated breast cancer.
